Understand the clinical trial landscape of rare disease trials.
Identify key analysis and segmentation of these trials by phase, single versus multinational trials, geography, sponsor type (industry versus non-industry), therapy area, indication, top sponsors, drug type, and DCT use.
Identify key analysis and segmentation of these trials by phase, single versus multinational trials, geography, sponsor type (industry versus non-industry), therapy area, indication, top sponsors, drug type, and DCT use.
Reasons to Buy
- Identify key analysis and segmentation of rare disease trials by phase, single versus multinational trials, geography, sponsor type (industry versus non-industry), therapy area, indication, top sponsors, drug type, and decentralized clinical trial use.
Table of Contents
- 1.Tables and Figures
- 2.Executive Summary
- 3.Introduction
- 4.Rare Disease
- 5.Key Findings
- 6.Appendix
Figure 1: Number of rare disease trials, by year (2004-24)
Figure 2: Rare disease trials, by regional distribution (2004-24)
Figure 3: Number of rare disease trials, by top five countries (2004-24)
Figure 4: Rare disease clinical trials, by year and phase (2004-24)
Figure 5: Top 10 TAs in rare disease clinical trials, by phase
Figure 6: Rare disease clinical trials, by sponsor type (2004-24)
Figure 7: Rare disease trials, by top 10 non-industry sponsors
Figure 8: Rare disease trials, by top 10 industry sponsors
Figure 9: Terminated/suspended/withdrawn rare disease trials, by leading sponsors
Figure 10: Rare disease clinical trials, by leading CROs
Figure 11: Single-country & multinational rare disease trials, by region (2004-24)
Figure 12 and 13: Rare disease clinical trials, by reason for termination and terminations by trial phase
Figure 14 and 15: Number of rare disease clinical trials, by virtual components
Figure 16 and 17: Rare disease clinical trials, by trial status and endpoint status
